Two studies reported different results using the allosteric AKT inhibitor MK-2206, which provides greater specificity, reduced side-effects and less toxicity compared to alkylphospholipid AKT inhibitors.4 A decrease in PC levels was observed in vitro in MDA-MB-468 breast cancer cells,27 while an increase in PC and a decrease in lactate levels were detected ex vivo in basal-like breast cancer tumours following treatment with MK-2206.26 The gene discussed is AKT1; the disease is breast carcinoma.